Sydbank: Expanded ALK approval is good news

It is good news that the FDA has approved ALK's ragweed allergy tablet for use in children – though it won't cause a huge increase in short term sales, says Sydbank senior analyst Søren Løntoft Hansen.
Sydbank/PR | Photo: Sydbank/PR
Sydbank/PR | Photo: Sydbank/PR

From now on, ALK-Abelló will also be able to market its allergy tablet, Ragwitek, as suitable for children aged 5 and above in the US. Although this is of course good news, it isn't something that will generate a lot of sales in the short term, says senior analyst at Sydbank, Søren Løntoft Hansen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading